DSIP side effects and risks

Reported side effects

• Transient sweating, headache, nausea or vertigo: 9/107 had one or more minor events in the IV withdrawal series; counts for each symptom were not given., mild. Stop and seek assessment if symptoms persist or worsen. (source)
• Low blood pressure: 2/107 in the IV withdrawal series; one worsened after another injection. Route specific community rates are unknown., serious. Fainting or severe dizziness needs urgent care. (source)
• Repeated discomfort with sweating and nausea: 1/107 in the IV withdrawal series; episodes lasted about 15 minutes and were classified as serious by FDA., serious. Stop and get medical assessment. (source)
• Faster heart rate: Observed during the 24 person anesthesia study; event counts and absolute change unavailable in the abstract., moderate. Report palpitations; chest pain or fainting needs urgent care. (source)
• Worse insomnia or next-day grogginess: Community reports; no reliable denominator or proven causal link., moderate. Stop if sleep or daytime alertness worsens; avoid driving while impaired. (source)
• Low mood or loss of motivation: One detailed user report at 100 mcg five nights weekly; no clinical incidence estimate., moderate. Stop and discuss mood changes with a clinician. (source)
• Allergic or immune reaction: FDA warns about potential immune reactions to peptide impurities or aggregates; DSIP incidence is unknown., serious. Breathing trouble, throat swelling or collapse needs emergency help. (source)

Stop and get help if

• Throat or tongue swelling, trouble breathing, or collapse: Stop exposure and call emergency services now.
• Fainting, severe dizziness or chest discomfort after dosing: Stop and get urgent medical assessment.
• Fever, spreading injection-site redness or feeling acutely unwell: Stop injections and get urgent assessment for infection or contamination.
• Very low blood sugar with confusion or inability to swallow: Use the prescribed emergency plan and call emergency services.

Who should avoid it

• pregnant: No adequate pregnancy or fetal-safety data. Avoid exposure during pregnancy.
• breastfeeding: Safety after taking DSIP while breastfeeding is unknown. Native DSIP-like material in milk does not establish drug safety.
• tryingToConceive: Reproductive safety has not been established. Avoid exposure while trying to conceive.
• under18: No established pediatric dose or adequate child-safety program. The reference uses an adult-only screen.
• other: A previous serious allergic reaction should stop re-exposure to that substance.
• other: Low blood pressure occurred with IV dosing, including worsening after repeat exposure.
• heartCondition: An anesthesia study found faster heart rate and altered heart-rate variability. Safety in heart disease is unknown.
• kidneyDisease: No validated dose adjustment or safety data for kidney disease. Elevated native DSIP signals during dialysis do not define drug clearance.
• liverDisease: Drug exposure, safety and dose adjustment in liver disease are unknown.
• psychiatricCondition: Users have reported low mood, low motivation or worse sleep. Controlled psychiatric safety data are lacking.
• sleepApnea: DSIP has not been shown to improve sleep apnea. Breathing pauses and daytime sleepiness need assessment.
• surgeryPlanned: Tell the anesthesia team about DSIP. One human trial found lighter anesthesia and faster heart rate.
• diabetes: A small uncontrolled combination-product study reported lower post-meal glucose. Its effect with diabetes medicines is unknown.
• testedAthlete: DSIP is not named on the 2026 list. S0 coverage depends on therapeutic approval status; obtain an anti-doping ruling.

Interactions

• Captopril and other ACE inhibitors: A review raises a theoretical peptidase interaction with captopril. Clinical effects and extension to other ACE inhibitors are untested.
• Anesthetic drugs: DSIP altered anesthesia depth and heart-rate signals with propofol and isoflurane. Other anesthetics were not established as safe combinations.
• Alcohol, opioids and sleep medicines: DSIP combination effects are poorly studied and may affect alertness unpredictably. It is not an established substitute for supervised withdrawal.
• Insulin and sulfonylureas: A small uncontrolled study reported lower post-meal glucose. A DSIP interaction is unproven; avoid self-adjusting diabetes medicines.

Product quality risks

• Health Canada’s DSIP-inclusive warning describes wrong amounts, unknown ingredients, microbes, endotoxins and particles in unauthorized peptides.
• FDA found inconsistent salt and identity descriptions in DSIP nomination documents and warned about peptide impurities and aggregates.
• No peer-reviewed survey quantifying purity or contamination of online DSIP vials was found. There is no reliable DSIP-specific failure rate.